Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

Vaccine

Volumn 18, Issue 17, 2000, Pages 1763-1772

  Gonzalez, Idalia M ^a   Karron, Ruth A ^a,b   Eichelberger, Maryna ^a   Walsh, Edward E ^c   Delagarza, Vincent W ^b   Bennett, Richard ^b   Chanock, Robert M ^d   Murphy, Brian R ^d   Clements Mann, Mary Lou ^a   Falsey, Ann R ^c  

^a Dept Molec Microbiol and Immunol   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adults; Elderly; Respiratory syncytial virus vaccines

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HN PROTEIN; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NASAL MUCOSA; REGRESSION ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0033997580     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00527-7     Document Type: Article

References (48)

1. Parrott R.H., Kim H.W., Arrobio J.O., Hodes D.S., Murphy B.R., Brandt C.D., Camargo E., Chanock R.M. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol. 98:1973;289-300.
2. Sims D.G., Downham M.A., McQuillin J., Gardner P.S. Respiratory syncytial virus infection in north-east England. Br. Med. J. 2:1976;1095-1098.
3. Pullan C.R., Hey E.N. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br. Med. J. 284:1982;1665-1669.
4. Rooney J.C., William H.E. The relationship between proved viral bronchiolitis and subsequent wheezing. J. Pediatrics. 79:1971;744-747.
5. Dowell S.F., Anderson L.J., Gary H.E. Jr, Erdman D.D., Plouffe J.F., File T.M. Jr, Marston B.J., Breiman R.F. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:1996;456-462.
6. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., Weiner L.B., Bonville C.A., Betts R.F. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
7. Vikerfors T., Grandien M., Olcan P. Respiratory syncytial virus infections in adults. Am. Rev. Respir. Dis. 136:1987;561-564.
8. Kimball A.M., Foy H.M., Cooney J.D., Allan J.D., Matlock M., Plorda J.J. Isolation of respiratory syncytial virus and influenza viruses from the sputum of patients hospitalized with pneumonia. J. Infect. Dis. 147:1983;181-184.
9. Wald T.G., Miller B.A., Drinka P. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J. Am. Geriatr. Soc. 43:1995;170-174.
10. Falsey A.R., McCann R.M., Hall W.J., Tanner M.A., Criddle M.M., Formica M.A., Irvine C.S., Kolassa J.E., Barker W.H., Treanor J.J. Acute respiratory tract infection in daycare centers for older persons. J. Am. Geriatr. 43:1995;30-36.
11. Zaroukian M.H., Kashyap G.H., Wentworth B.B. Respiratory syncytial virus infection: a cause of respiratory distress syndrome and pneumonia in adults. Am. J. Med. Sci. 295:1988;218-222.
12. Han L.L., Alexander J.P., Anderson L.J. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179:1999;25-30.
13. Fransen H., Sterner G., Forsgren M., Heigl Z., Wolontis S., Svedmyr A., Tunevall G. Acute lower respiratory illness in elderly patients with respiratory syncytial virus infection. Acta Medica Scand. 182:1967;323-330.
14. Fleming D.M., Cross K.W. Respiratory syncytial virus or influenza. Lancet. 342:1993;1507-1510.
15. Garvie D.G., Gray J. Outbreak of respiratory syncytial virus infection in the elderly. Br. Med. J. 281:1980;1253-1254.
16. Mathur U., Bentley D.W., Hall C.B. Concurrent respiratory syncytial virus and influenza A infection in the institutionalized elderly and chronically ill. Ann. Int. Med. 93:1980;49-52.
17. Morales P., Calder M.A., Inglia J.M., Murdoch P.S., Williamson J. A study of respiratory infections in the elderly to assess the role of respiratory syncytial virus. J. Infect. 7:1983;236-247.
18. Sorvillo F.J., Huic S.F., Strassberg M.A., Butsumyo A., Shaders W.X., Fannin S.K. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J. Infect. Dis. 9:1984;252-256.
19. Hart J. An outbreak of respiratory syncytial virus infection in an old people's home. J. Infect. 8:1984;259-261.
20. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:1986;543-546.
21. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98:1981;708-715.
22. Falsey A.R., Walsh E.E. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis. 177:1998;463-466.
23. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 14:1996;1214-1218.
24. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 15:1997;1130-1132.
25. Gorse G.J., Otto E.E., Powers D.C., Chambers G.W., Eickhoff C.S., Newman F.K. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 173:1996;285-290.
26. Gorse G.J., Campbell M.J., Otto E.E., Powers D.C., Chambers G.W., Newman F.K. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J. Infect. Dis. 172:1995;1-10.
27. Treanor J.J., Mattison H.R., Dumyati G., Yinnon A., Erb S., O'Brien D., Dolin R., Betts R.F. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117:1992;625-633.
28. Wright P.F., Karron R.A., Crowe J.E. Jr, Belshe R.B., Wittek A.C., Whitehead S.S., Murphy B.R. Evaluation of a live, attenuated respiratory syncytial virus (RSV) vaccine candidate, cpts 248/404, in infancy. Pediatr. Res. 43:1998;161A.
29. Wright PF, Karron RA, Crowe JE Jr, Belshe RB, Wittek AC, Whitehead SS, Murphy BR. Evaluation of a live, attenuated respiratory syncytial virus (RSV) vaccine candidate, cpts 248/404, in infancy. (submitted for publication).
30. Crowe J.E. Jr, Bui P.T., Davis A.R., Chanock R.M., Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 12:1994;783-790.
31. Karron R.A., Wright P.F., Crowe J.E. Jr, Clements M.L., Thompson J., Makhene M., Casey R., Murphy B.R. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. J. Infect. Dis. 176:1997;1428-1436.
32. Henkel J.H., Aberle S.W., Kundi M., Popow-Kraupp T. Improved detection of respiratory syncytial virus in nasal aspirates by seminested RT-PCR. J. Med. Virol. 53:1997;366-371.
33. Walsh E.E., Falsey A.A. A simple and reproducible method for collecting nasal secretions in frail elderly adults, for measurement of virus-specific IgA. J. Infect. Dis. 179:1999;1268-1273.
34. Anderson L.J., Hierholzer J.C., Bingham P.G., Stone Y.O. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1985;1050-1052.
35. Tristram D.A., Welliver R.C., Mohar C.K., Hogerman D.A., Hildreth S.W., Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:1993;191-195.
36. Paradiso P.R., Hildreth S.W., Hogerman D.A., Speelman D.J., Lewin E.B., Oren J., Smith D.H. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr. Infect. Dis. J. 13:1994;792-798.
37. Belshe R.B. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168:1993;1024-1029.
38. Piedra P.A., Grace S., Jewell A., Spinelli S., Bunting D., Hogerman D.A., Malinoski F., Hiatt P.W. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:1996;23-31.
39. Piedra P.A., Grace S., Jewell A., Spinelli S., Hogerman D.A., Malinoski F., Hiatt P.W. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr. Infect. Dis. J. 17:1998;217-224.
40. Groothuis J.R., King S.J., Hogerman D.A., Paradiso P.R., Simoes E.A. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177:1998;467-469.
41. Crowe J.E. Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine. 13:1995;415-421.
42. Denis F., Maunier M., Hessel L., Michel J.P., Gualde N., Dubois F., Barin F., Goudeau A. Hepatitis B vaccination in the elderly. J. Infect. Dis. 149:1984;1019.
43. Falsey A.R., Walsh E.E., Looney J.R., Kolassa J.E., Formica M.A., Criddle M.C., Hall W.J. A comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J. Med. Virol. 51:1999;221-226.
44. McCarthy D.O., Domurat F.M., Nichols J.E., Roberts N.J. Jr. Interleukin-1 inhibitor production by human mononuclear leukocytes and leukocyte subpopulations exposed to respiratory sycytial virus: analysis and comparison with the response to influenza virus. J. Leuk. Biol. 46:1969;189-198.
45. Salkind A.R., Nichols J.E., Roberts N.J. Jr. Suppressed expression of ICAM-1 and LFA-1 and abrogation of leukocyte collaboration after exposure of human mononuclear leukocytes to respiratory syncytial virus in vitro. J. Clin. Invest. 88:1991;505-511.
46. Roberts N.J. Jr, Prill A.H., Mann T.N. Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncytial virus. J. Exp. Med. 163:1986;511-519.
47. Salkind A.R., McCarthy D.O., Nichols J.E., Domurat F.M., Walsh E.E., Roberts N.J. Jr. Interleukin-1-inhibitor activity induced by respiratory syncytial virus: Abrogation of virus-specific and alternate human lymphocyte proliferative responses. J. Infect. Dis. 163:1991;71-77.
48. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St. Claire M., Elkins W.R., Collins P.L., Murphy B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:1999;3438-3442.